Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44043   clinical trials with a EudraCT protocol, of which   7319   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2019-002949-38
    Sponsor's Protocol Code Number:CVL-751-PD-001
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2020-02-28
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2019-002949-38
    A.3Full title of the trial
    A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP, 27 WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON’S DISEASE (TEMPO-1 TRIAL)
    ENSAYO DE FASE III DOBLE CIEGO, ALEATORIZADO, CONTROLADO CON PLACEBO, DE GRUPOS PARALELOS Y DE 27 SEMANAS PARA EVALUAR LA EFICACIA, LA SEGURIDAD Y LA TOLERABILIDAD DE DOS DOSIS FIJAS DE TAVAPADÓN EN LA ENFERMEDAD DE PARKINSON PRECOZ (ENSAYO TEMPO-1)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP, 27 WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON’S DISEASE (TEMPO-1 TRIAL)
    ENSAYO DE FASE III DOBLE CIEGO, ALEATORIZADO, CONTROLADO CON PLACEBO, DE GRUPOS PARALELOS Y DE 27 SEMANAS PARA EVALUAR LA EFICACIA, LA SEGURIDAD Y LA TOLERABILIDAD DE DOS DOSIS FIJAS DE TAVAPADÓN EN LA ENFERMEDAD DE PARKINSON PRECOZ (ENSAYO TEMPO-1)
    A.4.1Sponsor's protocol code numberCVL-751-PD-001
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorCerevel Therapeutics, LLC
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportCerevel Therapeutics, LLC
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationCerevel Therapeutics, LLC
    B.5.2Functional name of contact pointStephanie Pfister
    B.5.3 Address:
    B.5.3.1Street Address131 Dartmouth Street, Suite 502
    B.5.3.2Town/ cityBoston MA
    B.5.3.3Post code02116
    B.5.3.4CountryUnited States
    B.5.4Telephone number+18573312084
    B.5.6E-mailstephanie.pfister@cerevel.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameTavapadon 0.25mg
    D.3.2Product code CVL-751
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTAVAPADON
    D.3.9.1CAS number 1643489-24-0
    D.3.9.2Current sponsor codeTavapadon (CVL-751)
    D.3.9.3Other descriptive namePF-06649751
    D.3.9.4EV Substance CodeSUB198080
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number0.25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameTavapadon 1mg
    D.3.2Product code CVL-751
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTAVAPADON
    D.3.9.1CAS number 1643489-24-0
    D.3.9.2Current sponsor codeTavapadon (CVL-751)
    D.3.9.3Other descriptive namePF-06649751
    D.3.9.4EV Substance CodeSUB198080
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameTavapadon 5mg
    D.3.2Product code CVL-751
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTAVAPADON
    D.3.9.1CAS number 1643489-24-0
    D.3.9.2Current sponsor codeTavapadon (CVL-751)
    D.3.9.3Other descriptive namePF-06649751
    D.3.9.4EV Substance CodeSUB198080
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboTablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Patients (18 to 60 years age) who have diagnosis of Parkinson's Disease
    Pacientes (18 a 60 años de edad) con diagnóstico de enfermedad de Parkinson
    E.1.1.1Medical condition in easily understood language
    Patients (18 to 60 years age) with Parkinson' s Disease
    Pacientes (18 a 60 años de edad) con enfermedad de Parkinson
    E.1.1.2Therapeutic area Diseases [C] - Nervous System Diseases [C10]
    MedDRA Classification
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    •To assess the efficacy of 2 fixed doses of tavapadon in subjects with early PD
    •Evaluar la eficacia de 2 dosis fijas de tavapadón en sujetos con EP precoz
    E.2.2Secondary objectives of the trial
    To assess the safety and tolerability of 2 fixed doses of tavapadon in subjects with early PD
    Evaluar la seguridad y la tolerabilidad de 2 dosis fijas de tavapadón en sujetos con EP precoz
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    -Optional Future Biospeciment Research
    - Investigación futura opcional con muestras biológicas
    E.3Principal inclusion criteria
    1.,Male and female subjects aged 40 to 80 years, inclusive, at the time of signing the ICF.
    2.,Sexually active men or women of childbearing potential must agree to practice effective birth control, or remain abstinent during the trial and for 4 weeks after the last dose of trial treatment.
    3.,Subjects who are capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
    4.,Subjects who are able, in the opinion of the investigator, to understand the nature of the trial and comply with protocol requirements, including the prescribed dosage regimens, scheduled visits, laboratory tests, and other trial procedures.
    5.,Subjects with a diagnosis of that is consistent with the UK Parkinson’s Disease Society Brain Bank diagnostic criteria, with bradykinesia and motor asymmetry
    6.,Subjects with modified Hoehn and Yahr stage 1, 1.5, or 2.
    7.,Subjects with disease duration (from time of diagnosis) of <3 years and disease progression in the 3 years before signing the ICF.
    8.,Subjects with an MDS UPDRS Part II score ≥2 and Part III score ≥10 at the Screening Visit.
    9.,Subjects with early PD who, in the opinion of the investigator, require pharmacologic intervention for disease management.
    10.,Subjects who are treatment naïve or have a history of prior incidental treatment with dopaminergic agents (including L-Dopa and dopamine receptor agonist medications) for <3 months and not within 2 months of signing the ICF. Prior and concurrent use of MAO B inhibitors is permitted if use was initiated >90 days before signing of the ICF and the dosage will remain stable for the duration of the trial (ie, no change in the MAO B inhibitor dose is permitted during the trial).
    1.Hombres y mujeres de 40 a 80 años de edad, ambas inclusive, en el momento de la firma del FCI.

    2.Los hombres o mujeres sexualmente activos con potencial para procrear deben estar de acuerdo en utilizar un método anticonceptivo eficaz o practicar la abstinencia durante el ensayo y durante 4 semanas después de la última dosis del tratamiento del ensayo.

    3.Sujetos que sean capaces de dar su consentimiento informado firmado, lo cual incluye el cumplimiento de los requisitos y restricciones enumerados en el formulario de consentimiento informado (FCI) y en este protocolo.

    4.Sujetos que, según el criterio del investigador, puedan comprender la naturaleza del ensayo y cumplir los requisitos del protocolo, incluidas las pautas posológicas recetadas, las visitas programadas, los análisis de laboratorio y los demás procedimientos del ensayo.

    5.Sujetos con un diagnóstico que cumpla con los criterios de diagnóstico de la Parkinson's Disease Society Brain Bank del Reino Unido, con bradicinesia y asimetría motora.

    6.Sujetos con un estadio de Hoehn y Yahr modificado 1, 1,5 o 2.

    7.Sujetos con una duración de la enfermedad (desde el momento del diagnóstico) de <3 años y progresión de la enfermedad en los 3 años anteriores a la firma del FCI.

    8.Sujetos con una puntuación ≥2 en la MDS UPDRS, parte II y una puntuación ≥10 en la parte III en la visita de selección.

    9.Sujetos con EP precoz que, según el criterio del investigador, requieran intervención farmacológica para el control de la enfermedad.

    10.Sujetos que no hayan sido tratados previamente o que tengan antecedentes de tratamiento esporádico con fármacos dopaminérgicos (como la levodopa y medicamentos agonistas de los receptores de la dopamina) durante <3 meses y no en los 2 meses anteriores a haber firmado el FCI. Se permite el uso previo y simultáneo de inhibidores de la MAO B si el uso se inició >90 días antes de la firma del FCI y la administración permanecerá estable durante todo el ensayo (es decir, no se permite ningún cambio en la dosis de los inhibidores de la MAO B durante el ensayo).
    E.4Principal exclusion criteria
    1.,Subjects with a history or clinical features consistent with essential tremor, atypical or secondary parkinsonian syndrome (including, but not limited to, progressive supranuclear palsy, multiple system atrophy, cortico-basal degeneration, or drug induced or poststroke parkinsonism).
    2. Subjects with a history of nonresponse or insufficient response to L-Dopa or 2 or more other antiparkinsonian drugs at therapeutic dosages.
    3.,Subjects who have had previous surgical intervention (eg, deep brain stimulation) for PD or for whom such a procedure is planned or anticipated during the trial period.
    4.,Subjects with an acute or chronic, clinically significant medical or psychiatric condition, cognitive impairment, or laboratory abnormality that might increase the risk associated with trial participation or administration of trial treatment or interfere with the interpretation of the trial results or that, in the judgment of the investigator, would make the subject inappropriate for entry into this trial.
    Medical conditions that are minor or well controlled may be considered acceptable if the condition does not expose the subject to an undue risk of a significant AE or interfere with the assessments of safety or efficacy during the course of the trial. Subjects with symptoms of anxiety or depression that are not debilitating and that are stable or adequately controlled with non-prohibited medication are considered acceptable. The medical monitor should be contacted in any instance where the investigator is uncertain regarding the stability of a subject’s medical conditions(s) and the potential impact of the condition(s) on trial participation.
    5.,Subjects with a history or current diagnosis of a clinically significant impulse control disorder (Disruptive, Impulse Control, and Conduct Disorder per DSM 5) (American Psychiatric Association, 2013).
    6.,Subjects with the presence of or history of brain tumor, hospitalization for severe head trauma, epilepsy (as defined by the International League Against Epilepsy), or seizures
    7.,Subjects with a history of psychosis or hallucinations within the previous 12 months based on medical records or subject/caregiver feedback
    8.,Subjects who answer “yes” on the C-SSRS Suicidal Ideation Item 4 or Item 5 (Active Suicidal Ideation with Some Intent to Act, Without Specific Plan, or Active Suicidal Ideation with Specific Plan and Intent) and whose most recent episode meeting the criteria for C SSRS Item 4 or Item 5 occurred within the last 6 months, OR
    Subjects who answer “yes” on any of the 5 C-SSRS Suicidal Behavior Items (actual attempt, interrupted attempt, aborted attempt, preparatory acts, or behavior) and whose most recent episode meeting the criteria for any of these 5 C-SSRS Suicidal Behavior Items occurred within the last 2 years, OR
    Subjects who, in the opinion of the investigator, present a serious risk of suicide.
    9.,Subjects with substance abuse or dependence disorder, including alcohol, benzodiazepines, and opioids, but excluding nicotine, within the past 6 months (180 days).
    10.,Subjects with dementia or cognitive impairment that, in the judgement of the investigator, would exclude the subject from understanding the ICF or participating in the trial.
    11. Subjects with a MoCA score <26.
    12. Subjects who previously participated in any tavapadon trial, including this trial, and received IMP.
    13. Subjects who received treatment with any other investigational drug within 60 days before signing the ICF.
    1.Sujetos con antecedentes o signos clínicos sugerentes de temblores de origen desconocido, síndrome parkinsoniano atípico o secundario (incluidos, entre otros, parálisis supranuclear progresiva, atrofia multisistémica, degeneración cortico-basal o parkinsonismo inducido por medicamentos o posapoplejía).

    2.Sujetos con antecedentes de falta de respuesta o respuesta insuficiente a la levodoopa o a dos o más antiparkinsonianos en dosis terapéuticas.

    3.Sujetos que se han sometido a una intervención quirúrgica previa (p. ej., estimulación cerebral profunda) por la EP o aquellos que tienen programada una intervención de este tipo o que previsiblemente se someterán a ella durante el período del ensayo.

    4.Sujetos con una afección clínica o trastorno psiquiátrico, agudo o crónico, de importancia clínica, un trastorno cognitivo o una anomalía analítica que podrían aumentar el riesgo asociado a la participación en el estudio o a la administración del tratamiento del ensayo, o que podrían interferir en la interpretación de los resultados del estudio, o que, en opinión del investigador, podrían hacer que la participación del sujeto en este estudio no fuese oportuna. Las afecciones clínicas de menor importancia o bien controladas pueden considerarse aceptables si no exponen al sujeto a un riesgo excesivo de experimentar un AA significativo ni interfieren en las evaluaciones de la seguridad o eficacia durante el ensayo. Se considera aceptables a los sujetos con síntomas de ansiedad o depresión que no son debilitantes y que están estables o adecuadamente controlados con medicamentos no prohibidos. Debe establecerse contacto con el monitor médico en todos los casos en los que el investigador no esté seguro de la estabilidad de la afección clínica de un sujeto y de la posible influencia de la afección en la participación en el estudio.

    5.Sujetos con antecedentes o diagnósticos actuales de un trastorno de control de los impulsos clínicamente significativo (trastornos disruptivos del control de los impulsos y de la conducta conforme al DSM 5) (Asociación Americana de Psiquiatría, 2013).

    6.Sujetos con presencia actual o antecedentes de tumor cerebral, hospitalización por traumatismo craneal grave, epilepsia (según la definición de la Liga Internacional contra la Epilepsia) o convulsiones.

    7.Sujetos con antecedentes de psicosis o alucinaciones en los 12 meses anteriores según la historia clínica o los comentarios del sujeto/cuidador.

    8.Sujetos que respondan "sí" a los puntos 4 o 5 sobre ideación suicida de la escala C-SSRS (Ideación suicida activa con cierta intención de actuar, sin plan específico o ideación suicida activa con plan específico e intención) y cuyo episodio más reciente que cumpla los criterios de los puntos 4 o 5 sobre ideación suicida de la escala C-SSRS haya ocurrido en los últimos 6 meses, O BIEN sujetos que respondan "sí" a cualquiera de los 5 puntos sobre comportamiento suicida de la escala C-SSRS (intento real, intento interrumpido, intento abortado, actos preparatorios o comportamiento) y cuyo episodio más reciente que cumpla los criterios de cualquiera de estos 5 puntos sobre comportamientos suicidas de la escala C-SSRS haya ocurrido en los últimos 2 años, O BIEN
    Sujetos que, en opinión del investigador, presentan un riesgo grave de suicidio.

    9.Sujetos que consuman drogas o sufran un trastorno de drogodependencia, como de alcohol, benzodiacepinas y opiáceos, excluyendo la nicotina, en los últimos 6 meses (180 días).

    10.Sujetos con demencia o un deterioro cognitivo que, a juicio del investigador, impedirían al sujeto comprender el FCI o participar en el ensayo.

    11.Sujetos con una puntuación de <26 en la MoCA.

    12.Sujetos que previamente han participado en cualquier ensayo con tavapadón, incluido este ensayo, y que han recibido el MI.

    13.Sujetos que han recibido tratamiento con cualquier otro medicamento en investigación en los 60 días anteriores a la firma del FCI.
    E.5 End points
    E.5.1Primary end point(s)
    Primary Efficacy Endpoint
    •Change from baseline to endpoint in the MDS UPDRS Parts II and III combined score
    •Variación desde el período basal hasta el final del ensayo clínico en la puntuación combinada de las Partes II y III de la escala MDS-UPDRS
    E.5.1.1Timepoint(s) of evaluation of this end point
    Baseline up through week 27
    Desde el período basal hasta la semana 27
    E.5.2Secondary end point(s)
    Key Secondary Efficacy Endpoints
    •Percentage of responders at endpoint, defined as a score of “much improved” or “very much improved” on the PGIC
    •Change from baseline to endpoint in the MDS UPDRS Part II score
    Criterios secundarios de valoración de la eficacia clave
    •Porcentaje de sujetos con respuesta al final del ensayo, definido como una puntuación de "mucha mejoría" o "muchísima mejoría" en el cuestionario PGIC
    •Variación desde el período basal hasta el final del ensayo clínico en la puntuación de la Parte II de la escala MDS-UPDRS
    E.5.2.1Timepoint(s) of evaluation of this end point
    Baseline up through week 27
    Desde el período basal hasta la semana 27
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned6
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA39
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Bulgaria
    Canada
    Czech Republic
    France
    Germany
    Hungary
    Israel
    Italy
    Poland
    Serbia
    Spain
    Sweden
    Ukraine
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LSLV
    Última visita del último paciente
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months4
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months10
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 200
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 322
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients No
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state12
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 268
    F.4.2.2In the whole clinical trial 522
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    Ninguno
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2020-04-07
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2020-03-12
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Sep 18 23:19:42 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA